Rafael Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Rafael Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $917.0K | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $637.0K | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $279.0K | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | $410.0K | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $802.0K | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | $4.91M | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | $4.93M | Oct 29, 2020 |
| FY2018 | Oct 31, 2018 | $1.11M | Oct 15, 2018 |
| FY2018 | Jul 31, 2018 | $1.22M | Oct 15, 2018 |
| FY2018 | Apr 30, 2018 | $1.09M | Oct 15, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $30.0K | Oct 29, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($290.0K) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($34.41M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($1.88M) | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | ($124.66M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($23.06M) | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | ($10.75M) | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | ($4.69M) | Oct 29, 2020 |
| FY2018 | Oct 31, 2018 | ($9.33M) | Oct 15, 2018 |
| FY2018 | Jul 31, 2018 | ($635.0K) | Oct 15, 2018 |
| FY2018 | Apr 30, 2018 | ($787.0K) | Oct 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($29.16M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($102.63M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($15.04M) | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | ($60.48M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($28.20M) | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | ($8.47M) | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | ($6.70M) | Oct 29, 2020 |
| FY2018 | Oct 31, 2018 | ($1.05M) | Oct 15, 2018 |
| FY2018 | Jul 31, 2018 | ($1.24M) | Oct 15, 2018 |
| FY2018 | Apr 30, 2018 | ($731.0K) | Oct 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $232.0K | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $4.17M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $6.31M | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | $8.74M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $4.91M | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | $2.39M | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | $1.03M | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $995.0K | Oct 4, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jul 31, 2022 | $16.98M | Oct 31, 2022 |
| FY2022 | Jul 31, 2021 | $17.02M | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | $9.12M | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | $8.82M | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $5.52M | Oct 4, 2019 |
| FY2018 | Jul 31, 2017 | $3.73M | Oct 15, 2018 |
| FY2018 | Jul 31, 2016 | $2.75M | Oct 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($18.92M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($7.80M) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | ($10.89M) | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | ($26.08M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($15.60M) | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | ($4.67M) | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | ($3.13M) | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | ($1.82M) | Oct 4, 2019 |
| FY2018 | Jul 31, 2017 | ($1.62M) | Oct 15, 2018 |
| FY2018 | Jul 31, 2016 | $72.0K | Oct 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $4.0K | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $143.0K | Oct 29, 2025 |
| FY2023 | Jul 31, 2022 | $2.0K | Oct 30, 2023 |
| FY2021 | Jul 31, 2021 | $206.0K | Oct 18, 2021 |
| FY2021 | Jul 31, 2020 | $534.0K | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | $399.0K | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $710.0K | Oct 4, 2019 |
| FY2018 | Jul 31, 2017 | $1.82M | Oct 15, 2018 |
| FY2018 | Jul 31, 2016 | $1.55M | Oct 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $114.11M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $96.83M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $98.83M | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | $118.32M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $154.06M | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | $136.35M | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | $142.14M | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $116.92M | Oct 4, 2019 |
| FY2018 | Jul 31, 2017 | $86.20M | Oct 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $15.74M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $10.57M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $2.20M | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | $21.11M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $17.35M | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | $5.82M | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | $17.38M | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $1.36M | Oct 4, 2019 |
| FY2018 | Jul 31, 2017 | $24.13M | Oct 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $94.39M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $82.19M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $100.29M | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | $100.52M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $122.29M | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | $116.80M | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | $110.98M | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | $106.70M | Oct 4, 2019 |
| FY2018 | Jul 31, 2017 | $52.74M | Oct 15, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $19.94M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $3.05M | Oct 29, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | ($232.26M) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | ($201.74M) | Oct 29, 2025 |
| FY2023 | Jul 31, 2023 | ($167.33M) | Oct 30, 2023 |
| FY2023 | Jul 31, 2022 | ($165.46M) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | ($40.80M) | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | ($16.26M) | Oct 18, 2021 |
| FY2020 | Jul 31, 2019 | ($5.84M) | Oct 29, 2020 |
| FY2019 | Jul 31, 2018 | ($1.11M) | Oct 4, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $52.77M | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | $2.68M | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | $21.50M | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | $26.54M | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | $7.85M | Oct 31, 2022 |
| FY2021 | Jul 31, 2020 | $6.21M | Oct 18, 2021 |
| FY2021 | Jul 31, 2019 | $12.02M | Oct 18, 2021 |
| FY2020 | Jul 31, 2018 | $15.80M | Oct 29, 2020 |
| FY2019 | Jul 31, 2017 | $11.76M | Oct 4, 2019 |
| FY2018 | Jul 31, 2016 | $2.34M | Oct 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | (1) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | (1) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | 0 | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | (6) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | (1) | Oct 31, 2022 |
| FY2018 | Oct 31, 2018 | 0 | Oct 15, 2018 |
| FY2018 | Jul 31, 2018 | 0 | Oct 15, 2018 |
| FY2018 | Apr 30, 2018 | 0 | Oct 15, 2018 |
| FY2018 | Jan 31, 2018 | 0 | Oct 15, 2018 |
| FY2018 | Oct 31, 2017 | 0 | Oct 15, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | (1) | Oct 29, 2025 |
| FY2025 | Jul 31, 2024 | (1) | Oct 29, 2025 |
| FY2024 | Jul 31, 2023 | 0 | Dec 20, 2024 |
| FY2023 | Jul 31, 2022 | (6) | Oct 30, 2023 |
| FY2022 | Jul 31, 2021 | (1) | Oct 31, 2022 |
| FY2018 | Oct 31, 2018 | 0 | Oct 15, 2018 |
| FY2018 | Jul 31, 2018 | 0 | Oct 15, 2018 |
| FY2018 | Apr 30, 2018 | 0 | Oct 15, 2018 |
| FY2018 | Jan 31, 2018 | 0 | Oct 15, 2018 |
| FY2018 | Oct 31, 2017 | 0 | Oct 15, 2018 |